Post-transplant lymphoproliferative disease in kidney transplant patients in the new immunosuppressive era

Clinical Transplantation

Volumn 11, Issue 3, 1997, Pages 243-249

  Ciancio, Gaetano ^b   Siquijor, Alex P ^b   Burke, George W ^b   Roth, David ^b   Cirocco, Robert ^b   Esquenazi, Violet ^b   Byrne Jr , Gerald E ^b   Miller, Joshua ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

Kidney immunosuppression; Lymphoma; Transplant

Indexed keywords

ACICLOVIR; AZATHIOPRINE; CYCLOSPORIN; GANCICLOVIR; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; FEMALE; GRAFT SURVIVAL; HEMODIALYSIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MALE; ORAL DRUG ADMINISTRATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANTIBODY FORMATION; CAUSE OF DEATH; CHILD; CYCLOSPORINE; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMP DEHYDROGENASE; INCIDENCE; KIDNEY TRANSPLANTATION; LYMPHOMA; MALE; MYCOPHENOLIC ACID; PRODRUGS; RENAL DIALYSIS; SURVIVAL RATE; TACROLIMUS;

EID: 0030913936     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. CIANCIO G, ROSEN A, LORETO-GRAND B, et al. The current advantage of FK506 in cadaver kidney transplantation. Transpl Proc 1996: 28: 1000.
2. CIANCIO G, ROTH D, BURKE G, et al. Renal transplantation in a new immunosuppressive era. Transpl Proc 1995: 27: 812
3. PENN I. Cancers complicating organ transplantation. N Engl J Med 1990: 23: 1767.
4. SWERDLOW S. Post-transplant lymphoproliferative disorders: A morphologic, phenotypic and genotypic spectrum of disease. Histopathology 1991: 20: 373.
5. GRUBER S, SKJEI K, SOTHERN R, et al. Cancer development in renal allograft recipients treated with conventional and cyclosporine immunosuppression. Transpl Proc 1991: 23: 1104.
6. COCKFIELD S, PREIKSAITIS J, JEWELL L, PARFREY N. Post-transplant lymphoproliferative disorder in renal allograft recipients. Transplantation 1993: 56: 88.
7. COCKFIELD S, PREIKSAITIS J, HARVEY E, et al. Is sequential use of ALG and OKT3 in renal transplants associated with an increased incidence of fulminant post-transplant lymphoproliferative disorder? Transpl Proc 1991: 23: 1106.
8. CRAIG F, GULLEY M, BANKS P. Post-transplantation lymphoproliferative disorders. Anatom Pathol 1993: 99: 265.
9. EMERY R, LAKE K. Post-transplantation lymphoproliferative disorder and OKT3. N Engl J Med 1991: 324: 1437.
10. LEBLOND V, SUTTON L, DORENT R, et al. Lymphoproliferative disorders after organ transplantation: A report of 24 cases observed in a single center. J Clin Oncol 1995: 13: 961.
11. SHEIL A, DISNEY A, MATHEW T AMISS N, EXCELL L. Cancer development in cadaveric donor renal allograft recipients treated with azathioprine or cyclosporine or azathioprine/cyclosporine. Transpl Proc 1991: 23: 1111.
12. KITAHARA S, MAKUUCHI M, KAWASAKI S, et al. Lymphoproliferative disorders after FK506. Lancet 1991: 337: 296.
13. NALESNIK M, DEMETRIS J, FUNG J, STARZL T. Lymphoproliferative disorders arising under immunosuppression with FK506: Initial observation in a large transplant population. Transpl Proc 1991: 23: 1108.
14. SWINNEN L, COSTANZO-NORDIN M, FISHER S, et al. Increased indigence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac transplant recipients. N Engl J Med 1990: 323: 1723.
15. FRANCIS J. Expression of Epstein-Barr virus in liver-transplant recipients with lymphoproliferative disease. N Engl J Med 1995: 329: 208.
16. KATO H, INAMOTO T, NAKAMURA H, et al. Soluble CD23 as a sensitive marker for Epstein-Barr virus-related disorders after liver transplantation. Transplantation 1993: 56: 1109.
17. RANDHAWA P, DEMETRIS J, NALESNIK M. EBER gene expression in Epstein-Barr virus-associated hematopoietic neoplasms. Leukemia and Lymphoma 1994: 13: 387.
18. VINOD R. Epstein-Barr viral infection and post-transplant lymphoproliferative disorders. Liver Transpl Surg 1995: 1: 100.
19. MORRISON V, DUNN D, MANIVEL C, et al. Clinical characteristics of post-transplant lymphoproliferative disorders. Am J Med 1994: 97: 14.
20. REYES J, TZAKIS A, GREEN M, et al. Post-transplant lymphoproliferative disorders occurring under primary FK 506 immunosuppression. Transpl Proc 1991: 23: 3044.
21. COX KL, LAWRENCE-MIYASAKI LS, GARCIA-KENNEDY R, et al. An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK 506 after liver transplantation. Transplantation 1995: 59: 524.